重要内容提示： | 回购方案首次披露日 | 2025/6/20 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 6 月 | 6 | 月 | 19 | 日~2026 | 年 | 18 日 | | 预计回购金额 | 500万元~1,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | | 0股 | | | | | | | 累计已回购股数占总股本比例 | | 0% | | | | | | | 累计已回购金额 | 0万元 | | | | | | | | 实际回购价格区间 | 0元/股~0元/股 | | | | | | | 一、回购股份的基本情况 证券代码：688105 证券简称：诺唯赞 公告编号：2025-030 南京诺唯赞生物科技股份有限公司 关于以集中竞价交易方式回购公司股份 ...

Core Viewpoint - The company announced a change in the designated sponsor representatives for its ongoing supervision during the initial public offering on the Sci-Tech Innovation Board, ensuring continuity in oversight of the use of raised funds [1]. Group 1 - The company received a letter from Huatai United Securities regarding the replacement of the sponsor representative for the ongoing supervision of its IPO on June 27, 2025 [1]. - Due to a job change, the original sponsor representative, Mr. Hong Jie Chao, is unable to continue his duties, leading to the appointment of Mr. Wang Jie Qiu as his replacement [1]. - The current sponsor representatives for the company's IPO supervision are now Mr. Wang Jie Qiu and Mr. Li Hao [1]. Group 2 - The company expressed gratitude to Mr. Hong Jie Chao for his contributions during the IPO and ongoing supervision period [1]. - Mr. Wang Jie Qiu has extensive experience in investment banking, having participated in multiple IPOs and bond issuances since 2011 [2]. - His previous projects include IPOs for Fengshan Group, Pengyao Environmental Protection, and several others, indicating a strong background in the industry [2].

证券代码：688105 证券简称：诺唯赞 公告编号：2025-029 南京诺唯赞生物科技股份有限公司 关于更换保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 华泰联合证券作为公司首次公开发行股票并在科创板上市的保荐机构及持 续督导机构，原委派洪捷超先生和李皓先生担任公司科创板首次公开发行持续督 导期的保荐代表人。现因洪捷超先生工作变动，无法继续履行持续督导职责。为 保证公司募集资金使用情况的持续督导工作有序进行，华泰联合证券现委派王杰 秋先生（简历详见附件）接替洪捷超先生，继续履行持续督导职责。 本次保荐代表人变更后，公司科创板首次公开发行股票的持续督导保荐代表 人为王杰秋先生和李皓先生。 公司董事会对洪捷超先生在公司首次公开发行股票并在科创板上市及持续 督导期间所做的工作表示衷心感谢！ 特此公告。 南京诺唯赞生物科技股份有限公司 董事会 2025 年 6 月 28 日 南京诺唯赞生物科技股份有限公司（以下简称"公司"）于 2025 年 6 月 27 日收到保荐机构华泰联合证券有限责任公司（以下简称"华泰 ...

Core Viewpoint - Multiple companies have announced significant developments, including investments, clarifications on business operations, and changes in control, which may present various investment opportunities and risks for stakeholders [2]. Company Announcements - **Hai Zheng Pharmaceutical** plans to establish a joint venture in synthetic biology with a registered capital of 350 million yuan, where Hai Zheng will contribute 260 million yuan, holding a 74.29% stake [3]. - **Jin Zhong Zi Jiu** clarified that its business scope remains unchanged despite media reports suggesting a shift away from liquor production, confirming that it will continue to focus on its core liquor business [4]. - **ST Gong Zhi** announced that its stock will resume trading on June 20, 2025, and enter a delisting period, with the last trading date expected to be July 10, 2025 [5]. - **Zhong Jing Electronics** confirmed that its production and operational conditions are normal, with no undisclosed significant matters [6]. - **Shan Jin International** is preparing for an overseas H-share issuance and listing on the Hong Kong Stock Exchange to enhance its global strategy [7]. - **Kang Da New Materials** intends to acquire at least 51% of Chengdu Zhongke Huamei Electronics to expand into the semiconductor integrated circuit sector [8]. - **Zhong Yan Chemical** agreed to a capital reduction for its subsidiary, which will result in it holding 100% of the subsidiary's equity, constituting a significant asset restructuring [9]. - **Tai Ji Co., Ltd.** announced a change in its actual controller to the Hubei Provincial State-owned Assets Supervision and Administration Commission, with stock resuming trading [10]. - **ST Yi Guo** plans to sell four Carrefour subsidiaries for 1 yuan, expecting to increase its net profit by approximately 572 million yuan, while focusing on its core home appliance business [11][12]. Performance Expectations - **Sheng Nuo Bio** anticipates a substantial increase in net profit for the first half of 2025, projecting a year-on-year growth of 253.54% to 332.10%, driven by strong performance in its peptide raw material business [13]. Share Buyback - **Nuo Wei Zan** intends to repurchase shares worth between 5 million and 10 million yuan to implement employee stock ownership plans, with a maximum repurchase price of 30 yuan per share [14]. Major Contracts - **Sai Sheng Pharmaceutical** signed a technology transfer contract for a new drug project with a total transaction amount of 20 million yuan, which will enhance its capabilities in the protein/antibody drug platform [15].

Core Viewpoint - Nanjing Novogene Bioinformatics Technology Co., Ltd. plans to repurchase its shares through centralized bidding, with a total repurchase amount ranging from RMB 5 million to RMB 10 million, aimed at implementing equity incentives or employee stock ownership plans [1][4][6]. Summary by Relevant Sections Repurchase Plan Details - The repurchase amount is set between RMB 5 million and RMB 10 million [1][4]. - The funding source for the repurchase will be the company's own funds [1][4]. - The maximum repurchase price is capped at RMB 30 per share, which does not exceed 150% of the average trading price over the last 30 trading days prior to the board's decision [1][4][6]. - The repurchase will be conducted through the Shanghai Stock Exchange's trading system [1][5]. - The duration for the repurchase is within 12 months from the board's approval date [1][4]. Purpose and Use of Repurchased Shares - The repurchased shares will be used for implementing equity incentives or employee stock ownership plans [1][4][8]. - If the company fails to implement these plans within three years after the repurchase, the unutilized shares will be canceled [1][4][12]. Shareholder and Management Plans - Major shareholders, including the actual controller and board members, have no plans to reduce their holdings in the next three to six months [2][10][11]. - The proposal for the repurchase was initiated by the actual controller and chairman, Mr. Cao Lin, based on confidence in the company's future development [12][13]. Financial Impact and Structure Changes - As of March 31, 2025, the company's total assets were RMB 5.266 billion, with net assets attributable to shareholders at RMB 3.901 billion [8]. - The repurchase amount, if at the upper limit of RMB 10 million, would represent approximately 0.02% of total assets and 0.26% of net assets [8]. - The repurchase is expected to have no significant impact on the company's operations, financial status, or future development [8]. Compliance and Authorization - The repurchase plan has been approved by more than two-thirds of the board members and does not require shareholder meeting approval [3][4]. - The management is authorized to handle all matters related to the repurchase, including adjustments to the plan as necessary [13][14].

证券代码：688105 证券简称：诺唯赞 公告编号：2025-027 南京诺唯赞生物科技股份有限公司 关于以集中竞价交易方式回购公司股份方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 南京诺唯赞生物科技股份有限公司（以下简称"公司"）拟通过集中竞价交易 方式回购部分公司已发行的人民币普通股（A 股），回购方案具体如下： ● 回购股份金额：人民币 500 万元（含）至 1,000 万元（含）。 ● 回购股份资金来源：公司自有资金。 ● 回购股份用途：用于实施股权激励或员工持股计划。若公司未能在股份回购完 成之后 3 年内实施股权激励或员工持股计划，未实施部分的股份将依法予以注销。 ● 回购股份价格：不超过人民币 30 元/股（含），该价格不高于公司董事会通过回 购决议前 30 个交易日公司股票交易均价的 150%。 ● 回购股份方式：通过上海证券交易所交易系统以集中竞价交易方式回购。 ● 回购股份期限：自董事会审议通过本次回购股份方案之日起 12 个月内。 ● 相关股东是否存在减持计划： 1、公司 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-028 南京诺唯赞生物科技股份有限公司 关于以集中竞价交易方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 南京诺唯赞生物科技股份有限公司（以下简称"公司"）拟通过集中竞价交易 方式回购部分公司已发行的人民币普通股（A 股），回购方案具体如下： ● 回购股份金额：人民币 500 万元（含）至 1,000 万元（含）。 ● 回购股份资金来源：公司自有资金。 ● 回购股份用途：用于实施股权激励或员工持股计划。若公司未能在股份回购完 成之后 3 年内实施股权激励或员工持股计划，未实施部分的股份将依法予以注销。 ● 回购股份价格：不超过人民币 30 元/股（含），该价格不高于公司董事会通过回 购决议前 30 个交易日公司股票交易均价的 150%。 ● 回购股份方式：通过上海证券交易所交易系统以集中竞价交易方式回购。 ● 回购股份期限：自董事会审议通过本次回购股份方案之日起 12 个月内。 ● 相关股东是否存在减持计划： 1、公司控 ...

Core Viewpoint - The company plans to repurchase shares with a budget of 5 million to 10 million yuan, with a maximum repurchase price of 30 yuan per share, aimed at implementing equity incentives or employee stock ownership plans [1] Summary by Categories Share Repurchase Plan - The company intends to repurchase between 166,700 to 333,300 shares, which represents 0.04% to 0.08% of the total share capital [1] - The repurchase period is set for 12 months from the date of board approval, with funding sourced from the company's own funds [1] Stakeholder Commitment - The company's controlling shareholder, actual controller, and board members have no plans to reduce their holdings in the next 3 to 6 months [1]

证券代码：688105 证券简称：诺唯赞 公告编号：2025-026 南京诺唯赞生物科技股份有限公司 关于公司董事长兼总经理、实际控制人 提议回购公司股份的提示公告 （一）回购股份的种类及回购方式：以集中竞价交易方式回购公司已发行的 人民币普通股（A 股）。 （二）回购股份的用途：用于股权激励或员工持股计划。若公司未能在股份 回购实施结果暨股份变动公告日后 3 年内使用完毕已回购股份，尚未使用的已回 购股份将予以注销。如国家相关政策调整，则回购方案按调整后的政策实行。 （三）回购股份的期限：自公司董事会审议通过回购方案之日起 12 个月内。 （四）回购股份的价格：不超过人民币 30 元/股（含）。 （五）回购股份的资金总额：不低于人民币 500 万元（含），不超过人民币 1,000 万元（含）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京诺唯赞生物科技股份有限公司（以下简称"公司"）于 2025 年 6 月 17 日收到公司董事长兼总经理、实际控制人曹林先生递交的《关于提议南京诺唯赞 生物科技股份有限公司回购公司 ...

诺唯赞公告，公司董事长兼总经理、实际控制人曹林提议以集中竞价交易方式回购公司股份，回购资金 总额为500万元-1000万元，回购价格不超过人民币30元/股，回购股份用于股权激励或员工持股计划。 若未能在回购实施结果暨股份变动公告日后3年内使用完毕，尚未使用的回购股份将予以注销。提议人 在提议前6个月内未买卖公司股份，并承诺在董事会上对回购议案投赞成票。 ...